BioMedica sues over AIM flop
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Oxford BioMedica, a biotech group backed by Oxford University, yesterday served High Court writs claiming almost pounds 1m from two underwriters who are alleged to have caused the group's AIM listing to flop in December after they withdrew their support, writes Magnus Grimond.
Kaj Kjellquist, a Swedish investor living in the UK, and Stockton Trading, a Bahamian-registered company, pulled out of the flotation just days before trading was due to begin.
The shares were placed at 88p, and lost almost 50 per cent of their value in first-day dealings. At yesterday's close the price was 50.5p, down 2p on the day.
The issue raised just over the pounds 5m Oxford said it needed to meet working capital requirements. The company is suing for most of the difference between this sum and pounds 6.15m, which was the underwritten sum mentioned in the flotation prospectus.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments